Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases during Q1 2019.

Merck Offering Refunds for 340B Overcharges

Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services Administration (HRSA) website.

The products include four NDCs for Merck’s antiviral Intron A and one NDC for its antiviral Sylatron. TICE BCG, a treatment for non-metastatic bladder cancer, also is covered. Merck has been allocating its supplies of TICE BCG due to supply constraints since January 2019.

Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer